TY - JOUR T1 - SARS-CoV-2 in human sewage in Santa Catalina, Brazil, November 2019 JF - medRxiv DO - 10.1101/2020.06.26.20140731 SP - 2020.06.26.20140731 AU - Gislaine Fongaro AU - Patrícia Hermes Stoco AU - Dóris Sobral Marques Souza AU - Edmundo Carlos Grisard AU - Maria Elisa Magri AU - Paula Rogovski AU - Marcos André Schörner AU - Fernando Hartmann Barazzetti AU - Ana Paula Christoff AU - Luiz Felipe Valter de Oliveira AU - Maria Luiza Bazzo AU - Glauber Wagner AU - Marta Hernández AU - David Rodriguez-Lázaro Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/29/2020.06.26.20140731.abstract N2 - We analysed human sewage located in Florianópolis (Santa Catalina, Brazil) from late October until the Brazil lockdown on early March. We detected SARS-CoV-2 in two samples collected independently on 27th November 2019 (5.49±0.02 log genome copies/L). Subsequent samplings were positive until 4th March 2020 (coinciding with the first COVID-19 case reported in Santa Catalina), with a SARS-CoV-2 RNA increase of one log (6.68±0.02 log genome copies/L). Our results show that SARS-CoV-2 has been circulating in Brazil since late November 2019, much earlier than the first reported case in the Americas (21st January 2020, USA).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was done with a special fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No aplicable as not human samples are used.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are available upon request ER -